tiprankstipranks
Axsome Therapeutics Inc (AXSM)
NASDAQ:AXSM
US Market
AXSM
Axsome Therapeutics
RESEARCH TOOLSreports

Axsome Therapeutics (AXSM) Stock Forecast & Price Target

2,343 Followers
See the Price Targets and Ratings of:

AXSM Analyst Ratings

Strong Buy
17Ratings
Strong Buy
16 Buy
1 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Axsome
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AXSM Stock 12 Month Forecast

Average Price Target

$226.29
▲(34.30% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Axsome Therapeutics in the last 3 months. The average price target is $226.29 with a high forecast of $260.00 and a low forecast of $202.00. The average price target represents a 34.30% change from the last price of $168.50.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"101":"$101","141":"$141","181":"$181","221":"$221","261":"$261"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":260,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$260.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":226.29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$226.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":202,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$202.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[101,141,181,221,261],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.78,178.56615384615384,185.3523076923077,192.13846153846154,198.92461538461538,205.71076923076924,212.49692307692308,219.28307692307692,226.06923076923078,232.85538461538462,239.64153846153846,246.42769230769233,253.21384615384616,{"y":260,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.78,175.97307692307692,180.16615384615383,184.35923076923078,188.5523076923077,192.7453846153846,196.93846153846152,201.13153846153847,205.32461538461538,209.5176923076923,213.71076923076922,217.90384615384613,222.09692307692308,{"y":226.29,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,171.78,174.10461538461539,176.42923076923077,178.75384615384615,181.07846153846154,183.40307692307692,185.7276923076923,188.0523076923077,190.37692307692308,192.70153846153846,195.02615384615385,197.35076923076923,199.67538461538462,{"y":202,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":134.99,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":149.03,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":182.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":185.88,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":166.38,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":171.78,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$260.00Average Price Target$226.29Lowest Price Target$202.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$260
Buy
54.30%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Imunon (NASDAQ: IMNN), Axsome Therapeutics (NASDAQ: AXSM) and Oric Pharmaceuticals (NASDAQ: ORIC)
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$223
Buy
32.34%
Upside
Reiterated
04/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on AXSM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$245
Buy
45.40%
Upside
Reiterated
04/02/26
Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Guggenheim Analyst forecast on AXSM
Yatin Suneja
Guggenheim
Guggenheim
$220→$245
Buy
45.40%
Upside
Reiterated
03/25/26
Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/21/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Monte Rosa Therapeutics (NASDAQ: GLUE) and Curis (NASDAQ: CRIS)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
―
Buy
―
Reiterated
03/13/26
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$222
Buy
31.75%
Upside
Reiterated
03/13/26
RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)
UBS Analyst forecast on AXSM
Ashwani Verma
UBS
UBS
$248→$251
Buy
48.96%
Upside
Reiterated
02/25/26
Axsome Therapeutics price target raised to $251 from $248 at UBSAxsome Therapeutics price target raised to $251 from $248 at UBS
Cantor Fitzgerald Analyst forecast on AXSM
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$153→$220
Buy
30.56%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Ionis Pharmaceuticals (NASDAQ: IONS) and Axsome Therapeutics (NASDAQ: AXSM)
Truist Financial Analyst forecast on AXSM
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$204→$207
Hold
22.85%
Upside
Reiterated
02/24/26
Axsome Therapeutics price target raised to $207 from $204 at Morgan StanleyAxsome Therapeutics price target raised to $207 from $204 at Morgan Stanley
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$193→$202
Buy
19.88%
Upside
Reiterated
02/24/26
Axsome Therapeutics price target raised to $202 from $193 at Wells FargoAxsome Therapeutics price target raised to $202 from $193 at Wells Fargo
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$178→$214
Buy
27.00%
Upside
Reiterated
02/23/26
Axsome Therapeutics: Auvelity Growth and Alzheimer’s Agitation Upside Support Buy Rating and $214 Target
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$225
Buy
33.53%
Upside
Reiterated
02/23/26
Buy Rating on Axsome: Strong Commercial Momentum, Expanding CNS Pipeline, and Attractive Valuation Upside
Wolfe Research Analyst forecast on AXSM
Rudy Li
Wolfe Research
Wolfe Research
$230
Buy
36.50%
Upside
Initiated
02/23/26
Axsome Therapeutics initiated with an Outperform at Wolfe ResearchAxsome Therapeutics initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on AXSM
Ram Selvaraju
H.C. Wainwright
H.C. Wainwright
$260
Buy
54.30%
Upside
Reiterated
04/02/26
Analysts Offer Insights on Healthcare Companies: Imunon (NASDAQ: IMNN), Axsome Therapeutics (NASDAQ: AXSM) and Oric Pharmaceuticals (NASDAQ: ORIC)
Piper Sandler Analyst forecast on AXSM
David Amsellem
Piper Sandler
Piper Sandler
$223
Buy
32.34%
Upside
Reiterated
04/02/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Jefferies Analyst forecast on AXSM
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$245
Buy
45.40%
Upside
Reiterated
04/02/26
Jefferies Sticks to Its Buy Rating for Axsome Therapeutics (AXSM)
Guggenheim Analyst forecast on AXSM
Yatin Suneja
Guggenheim
Guggenheim
$220→$245
Buy
45.40%
Upside
Reiterated
03/25/26
Guggenheim Keeps Their Buy Rating on Axsome Therapeutics (AXSM)
William Blair Analyst forecast on AXSM
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
03/21/26
Analysts Offer Insights on Healthcare Companies: Axsome Therapeutics (NASDAQ: AXSM), Monte Rosa Therapeutics (NASDAQ: GLUE) and Curis (NASDAQ: CRIS)
Mizuho Securities Analyst forecast on AXSM
Graig Suvannavejh
Mizuho Securities
Mizuho Securities
―
Buy
―
Reiterated
03/13/26
RBC Capital Analyst forecast on AXSM
Leonid Timashev
RBC Capital
RBC Capital
$222
Buy
31.75%
Upside
Reiterated
03/13/26
RBC Capital Remains a Buy on Axsome Therapeutics (AXSM)
UBS Analyst forecast on AXSM
Ashwani Verma
UBS
UBS
$248→$251
Buy
48.96%
Upside
Reiterated
02/25/26
Axsome Therapeutics price target raised to $251 from $248 at UBSAxsome Therapeutics price target raised to $251 from $248 at UBS
Cantor Fitzgerald Analyst forecast on AXSM
Pete Stavropoulos
Cantor Fitzgerald
Cantor Fitzgerald
$153→$220
Buy
30.56%
Upside
Reiterated
02/25/26
Analysts Offer Insights on Healthcare Companies: Fractyl Health, Inc. (NASDAQ: GUTS), Ionis Pharmaceuticals (NASDAQ: IONS) and Axsome Therapeutics (NASDAQ: AXSM)
Truist Financial Analyst forecast on AXSM
Joon Lee
Truist Financial
Truist Financial
―
Buy
―
Reiterated
02/24/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Morgan Stanley Analyst forecast on AXSM
Sean Laaman
Morgan Stanley
Morgan Stanley
$204→$207
Hold
22.85%
Upside
Reiterated
02/24/26
Axsome Therapeutics price target raised to $207 from $204 at Morgan StanleyAxsome Therapeutics price target raised to $207 from $204 at Morgan Stanley
Wells Fargo Analyst forecast on AXSM
Benjamin Burnett
Wells Fargo
Wells Fargo
$193→$202
Buy
19.88%
Upside
Reiterated
02/24/26
Axsome Therapeutics price target raised to $202 from $193 at Wells FargoAxsome Therapeutics price target raised to $202 from $193 at Wells Fargo
Bank of America Securities Analyst forecast on AXSM
Jason Gerberry
Bank of America Securities
Bank of America Securities
$178→$214
Buy
27.00%
Upside
Reiterated
02/23/26
Axsome Therapeutics: Auvelity Growth and Alzheimer’s Agitation Upside Support Buy Rating and $214 Target
Needham Analyst forecast on AXSM
Ami Fadia
Needham
Needham
$225
Buy
33.53%
Upside
Reiterated
02/23/26
Buy Rating on Axsome: Strong Commercial Momentum, Expanding CNS Pipeline, and Attractive Valuation Upside
Wolfe Research Analyst forecast on AXSM
Rudy Li
Wolfe Research
Wolfe Research
$230
Buy
36.50%
Upside
Initiated
02/23/26
Axsome Therapeutics initiated with an Outperform at Wolfe ResearchAxsome Therapeutics initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Axsome Therapeutics

3 Months
xxx
Success Rate
18/27 ratings generated profit
67%
Average Return
+13.15%
reiterated a xxx
 rating last month
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +13.15% per trade.
1 Year
Marc GoodmanLeerink Partners
Success Rate
31/32 ratings generated profit
97%
Average Return
+52.09%
reiterated a buy rating 6 months ago
Copying Marc Goodman's trades and holding each position for 1 Year would result in 96.88% of your transactions generating a profit, with an average return of +52.09% per trade.
2 Years
xxx
Success Rate
32/32 ratings generated profit
100%
Average Return
+79.49%
reiterated a xxx
 rating 6 months ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +79.49% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AXSM Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
1
0
2
3
4
Buy
27
43
44
39
21
Hold
22
22
21
11
11
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
50
65
67
53
36
In the current month, AXSM has received 25 Buy Ratings, 11 Hold Ratings, and 0 Sell Ratings. AXSM average Analyst price target in the past 3 months is 226.29.
Each month's total comprises the sum of three months' worth of ratings.

AXSM Financial Forecast

AXSM Earnings Forecast

Next quarter’s earnings estimate for AXSM is -$0.79 with a range of -$1.29 to -$0.21. The previous quarter’s EPS was -$0.56. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s earnings estimate for AXSM is -$0.79 with a range of -$1.29 to -$0.21. The previous quarter’s EPS was -$0.56. AXSM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Sales Forecast

Next quarter’s sales forecast for AXSM is $195.13M with a range of $163.80M to $211.73M. The previous quarter’s sales results were $196.00M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.
Next quarter’s sales forecast for AXSM is $195.13M with a range of $163.80M to $211.73M. The previous quarter’s sales results were $196.00M. AXSM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AXSM has Performed in-line its overall industry.

AXSM Stock Forecast FAQ

What is AXSM’s average 12-month price target, according to analysts?
Based on analyst ratings, Axsome Therapeutics Inc’s 12-month average price target is 226.29.
    What is AXSM’s upside potential, based on the analysts’ average price target?
    Axsome Therapeutics Inc has 34.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AXSM a Buy, Sell or Hold?
          Axsome Therapeutics Inc has a consensus rating of Strong Buy which is based on 16 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Axsome Therapeutics Inc’s price target?
            The average price target for Axsome Therapeutics Inc is 226.29. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $260.00 ,the lowest forecast is $202.00. The average price target represents 34.30% Increase from the current price of $168.5.
              What do analysts say about Axsome Therapeutics Inc?
              Axsome Therapeutics Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of AXSM?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.